Vaccine Ranking
Cross-source consensus on Vaccine Ranking from 1 sources and 6 claims.
1 sources · 6 claims
Benefits
Risks & contraindications
Comparisons
Other
Other
Highlighted claims
- HPV was the strongest overall candidate and ranked first in half of the importance and feasibility criteria. — Application of the WHO new vaccine introduction prioritisation and sequencing framework to guide evidence-based vaccine introduction decisions in Iran, 2025–2030
- RSV and varicella were not recommended for introduction within the next five years. — Application of the WHO new vaccine introduction prioritisation and sequencing framework to guide evidence-based vaccine introduction decisions in Iran, 2025–2030
- Seven vaccines were selected for detailed evaluation after Workshop I. — Application of the WHO new vaccine introduction prioritisation and sequencing framework to guide evidence-based vaccine introduction decisions in Iran, 2025–2030
- HPV's high priority was mainly linked to effectiveness, durability, complications, and DALY-related impact rather than antimicrobial-use reduction or incidence. — Application of the WHO new vaccine introduction prioritisation and sequencing framework to guide evidence-based vaccine introduction decisions in Iran, 2025–2030
- PCV for high-risk groups and RSV ranked highest for mortality impact. — Application of the WHO new vaccine introduction prioritisation and sequencing framework to guide evidence-based vaccine introduction decisions in Iran, 2025–2030
- RSV and chickenpox performed poorly on price, market availability, and funding sustainability. — Application of the WHO new vaccine introduction prioritisation and sequencing framework to guide evidence-based vaccine introduction decisions in Iran, 2025–2030